CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. 8-K

What Happened
Creative Medical Technology Holdings, Inc. announced on June 30, 2026 that holders of existing warrants agreed to cash‑exercise 2,790,340 warrants at $1.60 per share, producing aggregate gross proceeds of approximately $4.5 million (before fees). In return, the company reduced the original $2.86 exercise price to $1.60 and issued the holders new “inducement” warrants to purchase an additional 5,580,680 shares at $1.60 per share. The inducement warrants were issued in a private placement and will not be exercisable until the company obtains the stockholder approval required by Nasdaq; once approved they will be exercisable for five years. Separately, on July 1, 2026 the Compensation Committee approved a $100,000 bonus to CEO Timothy Warbington.

Key Details

• Existing warrants exercised: 2,790,340 shares at $1.60; aggregate gross proceeds ≈ $4.5 million (before advisory fees).
• New inducement warrants: cover 5,580,680 shares at $1.60; not exercisable until shareholder approval; five‑year exercise window after approval.
• Fees and expenses: Roth Capital Partners acted as financial advisor and will receive an 8% fee on gross proceeds and reimbursement of $50,000 of legal expenses.
• Registration: shares issuable on exercise of the existing warrants are registered (Form S‑3, effective Dec 12, 2025); the company agreed to file a resale registration for shares underlying the inducement warrants within 30 days.

Why It Matters
The transaction provides Creative Medical with an immediate cash infusion (roughly $4.5M gross) to fund working capital and general corporate purposes, but also creates potential future dilution: if all inducement warrants are exercised, up to a total of 8,371,020 shares could be issued (existing exercised shares plus inducement warrants). The inducement warrants’ lower $1.60 exercise price (vs. the prior $2.86) reduces per‑share proceeds and the advisers’ fees will reduce net cash received. Because the inducement warrants are blocked from exercise until shareholder approval and require a registration filing for resale, the timing of any dilution depends on future corporate approvals and SEC filings.